Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymoglobulin in Primary Cardiac Transplant Recipients
NCT03292861Phase 2Enrolling by invitation
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Sep 2018
- Primary completion
- Mar 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of antithymocyte globulin in cardiac allograft vasculopathy (CAV) and heart transplant rejection (2 arms), sponsored by Cedars-Sinai Medical Center. Primary endpoint: Percentage of Participants With Composite Efficacy Failure at 12 months. Started Sep 2018; status: enrolling by invitation.
02
Drugs
antithymocyte globulin
03
Conditions
cardiac allograft vasculopathy (CAV)heart transplant rejection
Beyond the preview
Go deeper on NCT03292861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03292861.